Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01962909 · ClinicalTrials.gov registry record · Early Phase 1
Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer
A Early Phase 1 study, sponsored by University of Virginia.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT01962909: Clinical Trial Early Phase 1 study, sponsored by University of Virginia.
NCT01962909 is a Early Phase 1 study that was terminated before completion, run by University of Virginia. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01962909, a Early Phase 1 study, was terminated before completion, sponsored by University of Virginia.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to study an experimental drug called PTP-01 that is being used as an imaging agent to diagnosis pancreatic cancer. Currently, pancreatic cancer is diagnosed using CT or MRI scans which miss small pancreatic cancers, particularly early stage disease. Researchers at the University of Virginia have identified a biomarker for pancreatic cancer called plectin, which is very specific for pancreatic cancer and not other, non-cancerous conditions involving the pancreas. These researchers have also developed PTP-01, an experimental drug that may be used with SPECT imaging to detect pancreatic cancer cells in humans.
Primary Outcome
requires a signal to background ratio of greater than or equal to 2:1 following a single intravenous bolus of PTP-01
Interventions
- DRUG PTP-01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-11 |
| Est. Completion | 2016-01 |
| Phase | Early Phase 1 |
Why NCT01962909 stopped before completion
NCT01962909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which PTP-01 is the first listed.
NCT01962909 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01962909 about?
NCT01962909 is a clinical study titled "Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer". The purpose of this clinical trial is to study an experimental drug called PTP-01 that is being used as an imaging agent to diagnosis pancreatic cancer. Currently, pancreatic cancer is diagnosed using CT or MRI scans which miss small pancreatic cancers, particularly early stage disease. Researchers ...
What is the current status of trial NCT01962909?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2013-11. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01962909?
The interventions under investigation include: PTP-01 (DRUG).
Who is sponsoring clinical trial NCT01962909?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01962909's enrollment target sits among peer trials
3 1948th of 2000 higher than 28 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia